Clinical Trials Browser

Phase 1/2 × Clinical Trials, Phase II as Topic × Clear all

NCT07446725 2026-03-03

A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT01171898 2026-02-24

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms

NCT07357519 2026-02-09

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Phase 1/2 Recruiting

Osteosarcoma

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04199741 2026-01-07

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Phase 1/2 Recruiting

Small Cell Lung Carcinoma

NCT02223208 2025-12-02

FIL_PTCL13

Phase 1/2 Active not recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT05958121 2025-11-18

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Phase 1/2 Recruiting

Neoplasms, Recurrence

NCT06364956 2025-08-11

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Phase 1/2 Recruiting

Urinary Bladder Neoplasms

NCT05491083 2025-07-25

ComPACT

Phase 1/2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06578624 2025-06-05

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Liposarcoma

NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

NCT05953350 2024-12-03

A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

Phase 1/2 Recruiting

Inhibition of Autophagy Synergizes Anti-tumor Effect

NCT02382406 2023-05-23

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Phase 1/2 Terminated

46 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT00547339 2022-12-07

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1/2 Completed

94 enrolled 14 charts

Prostatic Neoplasms

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Phase 1/2 Unknown

Adenocarcinoma, Carcinoma, Squamous Cell